Gilead Sciences

Amgen

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Alnylam Pharmaceuticals

Biogen

Illumina

United Therapeutics

Moderna

Viatris

ProShares Ultra Nasdaq Biotechnology

BIB provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.

Apple

Amazon

ANSYS

Boeing

F5 Networks

Alphabet

Hershey

IDEX

Intel

McDonald's

Microsoft

Smurfit WestRock PLC

Tesla

All eyes will remain on big tech this week with Microsoft, Amazon, Meta, and Apple set to report for Q2. Outlier earnings this week include - McDonald's & Boeing. During this second peak week of the Q2 season, nearly 2,500 companies are set to report.

Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?

Immunovant Inc

Terns Pharmaceuticals

Some of the market's favorite biotech stocks have created immense wealth, as in the recent weight-loss drug stock boom.  On May 26, Viking Therapeutics (NASDAQ: VKTX ) was trading around $20.25.

Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

Altimmune

Pyxis Oncology

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

Virtus Artificial Intelligence & Technology Opportunities Fund

Global X Artificial Intelligence & Technology ETF

ProShares Ultra Oil & Gas

Eaton Vance Enhanced Equity Income Fund

Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund

Eaton Vance Tax-Managed Global Diversified Equity Income Fund

abrdn Healthcare Investors 

iShares Nasdaq Biotechnology ETF

iShares Russell 2000 ETF

NVIDIA

Novo Nordisk

Invesco QQQ

First Trust Cloud Computing ETF

SPDR S&P 500 ETF Trust

ProShares Ultra S&P 500

Energy Select Sector SPDR Fund

Exxon Mobil

In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding factor for why so few stocks, think Magnificent 7, received the lion's share of buy-interest while most everything else suffered, including equity CEFs. But just because the Federal Reserve will continue its Quantitative Tapering doesn't mean that other Fed programs won't increase liquidity in other places.

Equity CEFs/ETFs: Top Picks For 2024 - Part II

Global X Cybersecurity ETF

Global X Autonomous & Electric Vehicles ETF

VanEck Green Metals ETF

Direxion Hydrogen ETF

Amplify Alternative Harvest ETF

VanEck Vectors Semiconductor ETF

These are some of the best ETFs to buy and hold heading into New Year 2023. Rather than being completely tied to the ebb and flow of single-stock ideas, you can gain access to a broad number of similar opportunities at a low price.

The 7 Best ETFs to Buy to Cover 2023's Biggest Investing Opportunities

AbbVie

Ardelyx

Axsome Therapeutics

Krystal Biotech

SPDR S&P Biotech ETF

Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

First Trust NYSE Arca Biotechnology Index Fund

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

Invesco Nasdaq Biotechnology ETF

iShares Neuroscience And Healthcare ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

Why Now Could Be The Time To Consider Neuroscience Investments

ProShares UltraShort Oil & Gas

Direxion Daily Energy Bear 2X Shares

Direxion Daily S&P Biotech Bull 3X Shares

MicroSectors U.S. Big Oil Index -3X Inverse Leveraged ETNs

MicroSectors Oil & Gas Exploration & Production -3X Inverse Leveraged ETN

Direxion Daily Retail Bull 3X Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares Ultra Nasdaq Cloud Computing ETF

Direxion Daily Dow Jones Internet Bull 3X Shares

Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Top Performing Leveraged/Inverse ETFs: 08/07/2022

ProShares UltraShort Nasdaq Biotechnology

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in development, hasn't received FDA approval, or hasn't been in the market long enough to establish a proven track record.

Cap-Weighting Crucial When Indexing Biotech

It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to offer investors great performance opportunities. The Wall Street Journal reports that investors who focused on COVID-19 stocks, short [.

How to Invest in Biotech in 2022

iShares Evolved U.S. Innovative Healthcare ETF

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Take a Look at the Top-Performing Biotech ETFs YTD

Defiance Nasdaq Junior Biotechnology ETF

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This follows the Monday news that the FDA fully approved the Pfizer and BioNTech COVID-19 vaccine, making it the first vaccine in the U.S. [.

Could Biotech ETFs Get Another Boost From JNJ News?

Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.

Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs

BioNTech SE

Pfizer

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officials are hoping will encourage those who have been reluctant to receive a vaccine to get vaccinated.

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be awarded such a designation. The move could generate additional confidence for more businesses, schools, and universities to embrace the current vaccine mandates.

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to future mutations.  “Delta has gone the way we were hoping it wouldn't.

As Covid Cases Mutate, the Biotech Industry Works to Keep Up

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

News for ProShares Ultra Nasdaq Biotechnology ETF (BIB)